Total Payments
$1.9M
2024 Payments
$295,030
Companies
70
Transactions
5,042
Medicare Patients
2,349
Medicare Billing
$3.0M
Payment Breakdown by Category
Other$1.3M (69.3%)
Travel$283,525 (14.7%)
Consulting$204,216 (10.6%)
Food & Beverage$94,816 (4.9%)
Research$7,006 (0.4%)
Education$770.68 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 641 | 65.0% |
| Travel and Lodging | $283,525 | 1,276 | 14.7% |
| Consulting Fee | $204,216 | 113 | 10.6% |
| Food and Beverage | $94,816 | 2,924 | 4.9% |
| Honoraria | $80,613 | 36 | 4.2% |
| Unspecified | $7,006 | 6 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,250 | 1 | 0.2% |
| Education | $770.68 | 44 | 0.0% |
| Grant | $239.52 | 1 | 0.0% |
Payments by Type
General
$1.9M
5,036 transactions
Research
$7,006
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $246,700 | 708 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $180,352 | 325 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $152,293 | 278 | $0 (2019) |
| Lilly USA, LLC | $149,254 | 393 | $0 (2024) |
| ABBVIE INC. | $115,533 | 423 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $114,313 | 233 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $108,838 | 181 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $104,731 | 179 | $0 (2024) |
| GENZYME CORPORATION | $83,716 | 165 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $83,288 | 96 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $295,030 | 691 | Amgen Inc. ($63,002) |
| 2023 | $309,946 | 708 | Amgen Inc. ($89,933) |
| 2022 | $263,943 | 662 | Amgen Inc. ($65,880) |
| 2021 | $232,027 | 547 | Mallinckrodt Hospital Products Inc. ($51,746) |
| 2020 | $122,022 | 395 | Lilly USA, LLC ($30,632) |
| 2019 | $316,178 | 779 | Mallinckrodt Enterprises LLC ($95,535) |
| 2018 | $227,242 | 694 | Novartis Pharmaceuticals Corporation ($74,288) |
| 2017 | $158,811 | 566 | Novartis Pharmaceuticals Corporation ($53,814) |
All Payment Transactions
5,042 individual payment records from CMS Open Payments — Page 1 of 202
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: RESPIRATORY | ||||||
| 12/18/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $37.34 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $6,900.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,040.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,860.00 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $620.00 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $255.10 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $115.10 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $97.43 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $97.43 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $70.04 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | Cash or cash equivalent | $43.81 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $41.54 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $41.54 | General |
| Category: Immunology | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Education | In-kind items and services | $10.29 | General |
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $9.94 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $134.31 | General |
| Category: Inflammation | ||||||
| 12/15/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $76.72 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $96.06 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Travel and Lodging | In-kind items and services | $111.38 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | Cash or cash equivalent | $90.48 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Travel and Lodging | Cash or cash equivalent | $48.71 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/12/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Travel and Lodging | Cash or cash equivalent | $41.54 | General |
| Category: LUPUS NEPHRITIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $5,917 | 3 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $974.82 | 2 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $114.46 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 491 | 72,122 | $2.4M | $743,874 |
| 2022 | 12 | 565 | 57,264 | $1.3M | $490,207 |
| 2021 | 12 | 618 | 85,799 | $2.2M | $1.1M |
| 2020 | 14 | 675 | 39,709 | $1.5M | $707,043 |
Total Patients
2,349
Total Services
254,894
Medicare Billing
$3.0M
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 11 | 8,700 | $832,900 | $260,459 | 31.3% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 18 | 54,800 | $713,200 | $211,230 | 29.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 242 | 836 | $225,720 | $76,206 | 33.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 41 | 4,260 | $226,500 | $73,722 | 32.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 11 | 2,560 | $220,790 | $67,262 | 30.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 41 | 252 | $86,940 | $24,301 | 28.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 61 | 447 | $84,483 | $23,900 | 28.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $9,545 | $2,717 | 28.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 96 | $10,560 | $2,118 | 20.1% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 14 | 30 | $6,990 | $1,866 | 26.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 118 | $1,770 | $92.50 | 5.2% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 15 | 48,800 | $532,400 | $218,471 | 41.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 279 | 936 | $252,772 | $82,813 | 32.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 11 | 2,690 | $201,750 | $77,008 | 38.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 39 | 3,900 | $104,460 | $61,378 | 58.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 36 | 202 | $69,690 | $19,991 | 28.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 56 | 346 | $65,394 | $19,420 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $14,110 | $4,075 | 28.9% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2022 | 16 | 45 | $10,485 | $3,022 | 28.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 17 | 97 | $10,670 | $2,197 | 20.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 13 | 17 | $4,590 | $931.30 | 20.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 34 | 69 | $4,416 | $801.33 | 18.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 15 | 128 | $1,920 | $98.30 | 5.1% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 14 | 8,650 | $640,100 | $348,738 | 54.5% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 19 | 52,000 | $572,000 | $295,489 | 51.7% |
About Dr. Dhiman Basu, MD
Dr. Dhiman Basu, MD is a Internal Medicine healthcare provider based in Colleyville, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336266964.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dhiman Basu, MD has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $295,030 received in 2024. These payments were reported across 5,042 transactions from 70 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Basu has provided services to 2,349 Medicare beneficiaries, totaling 254,894 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology, Student in an Organized Health Care Education/Training Program
- Location Colleyville, TX
- Active Since 03/26/2007
- Last Updated 03/01/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1336266964
Products in Payments
- ACTHAR (Biological) $257,024
- COSENTYX (Biological) $144,224
- TAVNEOS (Drug) $132,084
- LUPKYNIS (Drug) $114,212
- SAPHNELO (Biological) $103,590
- Otezla (Drug) $92,729
- SIMPONI ARIA (Biological) $75,888
- TALTZ (Drug) $69,958
- PURIFIED CORTROPHIN GEL (Drug) $66,019
- BENLYSTA (Biological) $59,326
- Tavneos (Drug) $58,472
- TREMFYA (Drug) $55,392
- KEVZARA (Drug) $52,872
- RINVOQ (Biological) $50,296
- XELJANZ (Drug) $40,981
- Bimzelx (Biological) $38,254
- KEVZARA (Biological) $34,904
- Humira (Biological) $26,216
- DUZALLO (Drug) $25,994
- Actemra (Biological) $24,596
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Colleyville
Dr. Lorrie Hayes, M.d, M.D
Internal Medicine — Payments: $6,389
Internal Medicine $6,389
Adel Zakhary, Md, MD
Internal Medicine — Payments: $5,665
Internal Medicine $5,665
Rehan Khan, Md, MD
Internal Medicine — Payments: $3,585
Internal Medicine $3,585
Janie Simmons, Md, MD
Internal Medicine — Payments: $2,287
Internal Medicine $2,287
Iram Hamdard, Md, MD
Internal Medicine — Payments: $2,253
Internal Medicine $2,253
Jonathan Richard, M.d., P.a, M.D., P.A
Internal Medicine — Payments: $1,805
Internal Medicine $1,805